New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
08:41 EDTTINYHarris & Harris reports NAV per share $3.93 as of Dec. 31 vs. $4.13 last year
Harris & Harris reported that, as of December 31, 2013, its net asset value and net asset value per share were $122,701,575 and $3.93, respectively. Reports total assets as of December 31, 2013 of $125,063,946 vs $131,990,250 last year and total shares outstanding as of December 31, 2013 of 31,197,438.
News For TINY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:08 EDTTINYSource Capital Group to hold a conference
Subscribe for More Information
February 3, 2016
09:32 EDTTINYHarris & Harris, Mersana Therapeutics, expand partnership with Technip
Harris & Harris notes the announcement by its portfolio company, Mersana Therapeutics, that Mersana and Takeda Pharmaceutical have entered a new strategic partnership granting Takeda rights to Mersana's lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana's Fleximer antibody-drug conjugate, or ADC, platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs. XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumors, including breast, gastric and non-small cell lung cancers. Mersana will receive an upfront payment of $40M and an additional payment of $20M upon clearance of the IND for XMT-1522 by the FDA. Subject to the success of the XMT-1522 and ADC programs, Mersana is eligible to receive milestone payments of more than $750 million combined, as well as royalties. Takeda will also invest up to $20M in equity in future rounds of Mersana financing.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use